Mathew Aby J.'s Form 4 filing
Biolife Solutions Inc (BLFS) · filed May 30, 2025
- Accession no.
- 0001628280-25-028700
- Filed
- May 30, 2025
- Trade date
- May 28-29, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $11.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mathew Aby J.CIK 0001556355 | Officer (EVP & Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2025 | Common Stock | SSaleDisposed | −521 | $22.46 | −$11,701.66 | 308,486 | Direct | |
| May 29, 2025 | Common Stock | AGrant or awardAcquired | +45,269 | –F2 | – | 353,755 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the fourth anniversary of the measurement date of 05-29-2025.
Referenced by the price of 1 transaction in Table I.